-
2022-502357-34-00
5
2023-09-27
Extensive Stage Small Cell Lung Cancer
-
2023-507778-42-00
4
2023-03-08
Non-Small Cell Lung Cancer II, III
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2023-509283-14-00
1
2022-04-25
Advanced non-small cell lung cancer
-
2023-508963-58-00
4
2022-01-31
Symptomatic hypertrophic cardiomyopathy (HCM)
-
2024-510690-16-00
5
2022-01-31
Relapsed/refractory follicular lymphoma
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2024-515273-10-00
7
2021-10-19
Relapsed or refractory Multiple Myeloma (r/r MM)
-
2024-512982-15-00
5
2021-06-28
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
-
2024-514542-37-00
9
2020-08-13
Select advanced solid tumors and Non-Small Cell Lung Cancer with MET a
-
2024-512606-25-00
7
2019-12-20
Advanced Solid Tumors
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-509318-13-00
6
2018-01-15
Multiple indications
-
2024-517091-38-00
3
2025-11-25
Head and neck squamous cell carcinoma
-
2024-520050-38-00
5
2025-09-18
Extensive stage small cell lung cancer (ES-SCLC). S
-
2025-520520-17-00
5
2025-09-05
Heterozygous familial hypercholesterolaemia
-
2025-520521-21-00
5
2025-09-02
Hyperlipidemia
-
2024-519575-26-00
4
2025-07-25
Chronic pulmonary aspergillosis (CPA)
-
2024-512925-95-00
5
2025-05-16
Advanced/Metastatic Breast Cancer
-
2024-515772-12-00
4
2025-04-18
Lung neoplasm malignant (Stage IV Non-small cell lung cancer)
-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2024-510719-31-00
5
2025-01-24
Moderate to Severe Vasomotor Symptoms (VMS)
-
2024-511650-50-00
5
2025-01-17
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2023-505989-29-00
5
2024-11-21
Extensive stage small cell lung cancer (ES-SCLC)